WSO - February 2023 - 222

222
International Journal of Stroke 18(2)
Keywords
First pass effect, multi-pass effect, large vessel occlusion, posterior circulation stroke
Received: 18 November 2021; accepted: 24 February 2022
Introduction
Complete successful recanalization, defined as the presence
of a modified Thrombolysis In Cerebral Infarction
(mTICI) of 3, has been widely associated with maximal
benefits in functional outcome at 3 months.1,2
The first pass effect (FPE), defined as the achievement
of mTICI 3 in a single pass of the endovascular thrombectomy
device, has been described as an independent predictor
of good outcomes in patients with large vessel occlusion
(LVO) undergoing endovascular thrombectomy (EVT) in
anterior circulation stroke.3,4 Some specific variables, such
as the use of a balloon guide catheter and thrombus location,
have been related to this FPE.5
Despite the lack of clear evidence of the clinical benefit of
EVT in posterior circulation large vessel occlusion (PC-LVO),
current guidelines recommend treating these patients endovascularly.6-9
The factors associated with FPE on PC-LVO and its
impact on functional outcome is still poorly understood.10-13
We aimed to study the frequency, characteristics, and
predictors of FPE on a PC-LVO population as well as the
factors associated with functional independence at 3 months.
Method
Study population
CICAT (Codi Ictus Catalunya) is a government-mandated,
prospective, hospital-based dataset in which all stroke codes
are included in Catalonia. From January 2016 to January
2020, a total of 24,553 consecutive stroke codes were
reported. A total of 3167 EVT were performed, and 41
(1.29%) patients were excluded from the analysis due to lack
of 3 months follow-up. Finally, 265 patients with pc-LVO
who were fully studied were included in the study (Figure 1).
All patients included in this study have an angiographic
confirmation of acute arterial occlusion of the basilar artery,
posterior cerebral artery (PCA), or intracranial vertebral
artery, less than 12 hours from stroke onset, a baseline pcASPECTS
⩽6 and a National Institute of Health Stroke
Score (NIHSS)⩾6 or high disabling symptomatology.
The purpose of this study was approved by the governmental
Catalan Review Board and the local Ethical
Committee (codi CEIM 2021.071).
Variables
We collected demographical, clinical, and radiological data
from all the patients who underwent EVT with at least one
device pass.
International Journal of Stroke, 18(2)
In the current study, complete successful recanalization
was defined by the presence of a modified Thrombolysis In
Cerebral Infarction (mTICI) of 3 in the final cerebral angiography.
FPE was considered if mTICI 3 was achieved in
the first pass of the device. All other patients were classified
in " non-FPE " group. For a second analysis, if mTICI 3
was achieved beyond the first pass, it was defined as multipass
effect (MPE).
Neurological status was assessed by certified stroke
neurologists at admission and during the whole followup
by using the NIHSS, and all endovascular procedures
were completed by neurointerventionsts and
neuroanesthesiologists.
The occlusion site was evaluated by computed tomography
angiography and confirmed by cerebral angiography
run prior to the EVT.
Functional outcome at 3 months was centrally assessed
by blinded evaluators of the Catalan Stroke Program using
a structured telephone interview of the modified Rankin
Score (mRS).
The primary outcome was the rate of functional independence
(mRS score ⩽ 2) at 3 months. Secondary outcomes
were anesthesia choice, technique during EVT, and
mortality at 3 months.
Statistical analysis
The baseline characteristics were compared using the Student
t test or the Mann-Whitney U test for continuous variables
and the χ2 test for categorical variables. Univariate analyses
were performed to study variables associated with clinical
outcome and FPE. Continuous variables are shown as mean
(standard deviation, SD) or median [interquartile intervals]
and were compared with the Student t test, analysis of variance,
Mann-Whitney, or Kruskal-Wallis tests as appropriate.
Categorical variables were reported as proportions.
Logistic regression was used to study the association
between FPE and the primary outcome and to adjust for
possible confounders. Variables showing a trend toward
significance (p value < .1) were entered in the multivariable
logistic models.
Data were analyzed with SPSS version 22.0 software,
and all tests were performed with a 5% significance level.
Results
Two hundred and sixty-five patients were included in the
study. The median age was 72 [63-80] years and 103
(38.9%) were female.

WSO - February 2023

Table of Contents for the Digital Edition of WSO - February 2023

February 2023
WSO - February 2023 - Cover1
WSO - February 2023 - 122
WSO - February 2023 - 123
WSO - February 2023 - February 2023
WSO - February 2023 - 125
WSO - February 2023 - 126
WSO - February 2023 - 127
WSO - February 2023 - 128
WSO - February 2023 - 129
WSO - February 2023 - 130
WSO - February 2023 - 131
WSO - February 2023 - 132
WSO - February 2023 - 133
WSO - February 2023 - 134
WSO - February 2023 - 135
WSO - February 2023 - 136
WSO - February 2023 - 137
WSO - February 2023 - 138
WSO - February 2023 - 139
WSO - February 2023 - 140
WSO - February 2023 - 141
WSO - February 2023 - 142
WSO - February 2023 - 143
WSO - February 2023 - 144
WSO - February 2023 - 145
WSO - February 2023 - 146
WSO - February 2023 - 147
WSO - February 2023 - 148
WSO - February 2023 - 149
WSO - February 2023 - 150
WSO - February 2023 - 151
WSO - February 2023 - 152
WSO - February 2023 - 153
WSO - February 2023 - 154
WSO - February 2023 - 155
WSO - February 2023 - 156
WSO - February 2023 - 157
WSO - February 2023 - 158
WSO - February 2023 - 159
WSO - February 2023 - 160
WSO - February 2023 - 161
WSO - February 2023 - 162
WSO - February 2023 - 163
WSO - February 2023 - 164
WSO - February 2023 - 165
WSO - February 2023 - 166
WSO - February 2023 - 167
WSO - February 2023 - 168
WSO - February 2023 - 169
WSO - February 2023 - 170
WSO - February 2023 - 171
WSO - February 2023 - 172
WSO - February 2023 - 173
WSO - February 2023 - 174
WSO - February 2023 - 175
WSO - February 2023 - 176
WSO - February 2023 - 177
WSO - February 2023 - 178
WSO - February 2023 - 179
WSO - February 2023 - 180
WSO - February 2023 - 181
WSO - February 2023 - 182
WSO - February 2023 - 183
WSO - February 2023 - 184
WSO - February 2023 - 185
WSO - February 2023 - 186
WSO - February 2023 - 187
WSO - February 2023 - 188
WSO - February 2023 - 189
WSO - February 2023 - 190
WSO - February 2023 - 191
WSO - February 2023 - 192
WSO - February 2023 - 193
WSO - February 2023 - 194
WSO - February 2023 - 195
WSO - February 2023 - 196
WSO - February 2023 - 197
WSO - February 2023 - 198
WSO - February 2023 - 199
WSO - February 2023 - 200
WSO - February 2023 - 201
WSO - February 2023 - 202
WSO - February 2023 - 203
WSO - February 2023 - 204
WSO - February 2023 - 205
WSO - February 2023 - 206
WSO - February 2023 - 207
WSO - February 2023 - 208
WSO - February 2023 - 209
WSO - February 2023 - 210
WSO - February 2023 - 211
WSO - February 2023 - 212
WSO - February 2023 - 213
WSO - February 2023 - 214
WSO - February 2023 - 215
WSO - February 2023 - 216
WSO - February 2023 - 217
WSO - February 2023 - 218
WSO - February 2023 - 219
WSO - February 2023 - 220
WSO - February 2023 - 221
WSO - February 2023 - 222
WSO - February 2023 - 223
WSO - February 2023 - 224
WSO - February 2023 - 225
WSO - February 2023 - 226
WSO - February 2023 - 227
WSO - February 2023 - 228
WSO - February 2023 - 229
WSO - February 2023 - 230
WSO - February 2023 - 231
WSO - February 2023 - 232
WSO - February 2023 - 233
WSO - February 2023 - 234
WSO - February 2023 - 235
WSO - February 2023 - 236
WSO - February 2023 - 237
WSO - February 2023 - 238
WSO - February 2023 - 239
WSO - February 2023 - 240
WSO - February 2023 - 241
WSO - February 2023 - 242
WSO - February 2023 - 243
WSO - February 2023 - 244
WSO - February 2023 - 245
WSO - February 2023 - 246
WSO - February 2023 - 247
WSO - February 2023 - 248
WSO - February 2023 - 249
WSO - February 2023 - 250
WSO - February 2023 - 251
WSO - February 2023 - Cover4
https://europe.nxtbook.com/nxteu/sageuk/wso_202404
https://europe.nxtbook.com/nxteu/sageuk/ukstrokeforum_202402_supp
https://europe.nxtbook.com/nxteu/sageuk/wso_202403
https://europe.nxtbook.com/nxteu/sageuk/wso_202402
https://europe.nxtbook.com/nxteu/sageuk/wso_202401
https://europe.nxtbook.com/nxteu/sageuk/wso_2023123_US_UKOnly
https://europe.nxtbook.com/nxteu/sageuk/wso_2023123_ROW
https://europe.nxtbook.com/nxteu/sageuk/wso_2023101
https://europe.nxtbook.com/nxteu/sageuk/wso_202308
https://europe.nxtbook.com/nxteu/sageuk/wso_202307
https://europe.nxtbook.com/nxteu/sageuk/wso_202306
https://europe.nxtbook.com/nxteu/sageuk/wso_202304
https://europe.nxtbook.com/nxteu/sageuk/wso_202303
https://europe.nxtbook.com/nxteu/sageuk/wso_202302
https://europe.nxtbook.com/nxteu/sageuk/wso_202301
https://www.nxtbookmedia.com